NCT06968195View on ClinicalTrials.gov

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

May 30, 2029

Conditions
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaRecurrent Hepatocellular CarcinomaRefractory Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
BIOLOGICAL

Anti-GPC3-CAR Autologous T Lymphocytes

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood and tissue sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER